Bristol Myers Squibb (NYSE:BMY) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Bristol Myers Squibb (NYSE:BMY) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

BMY has been the topic of several other research reports. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Bank of America lowered their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Up 3.7%

Shares of NYSE:BMY opened at $57.45 on Friday. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a market cap of $117.31 billion, a price-to-earnings ratio of 16.14, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm’s 50 day moving average price is $57.06 and its 200 day moving average price is $57.27.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the business earned $1.80 EPS. Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts predict that Bristol Myers Squibb will post 6.32 earnings per share for the current fiscal year.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Basecamp Wealth Advisors LLC lifted its holdings in Bristol Myers Squibb by 13.8% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 6,462 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 786 shares in the last quarter. FAS Wealth Partners Inc. grew its stake in shares of Bristol Myers Squibb by 2.1% during the first quarter. FAS Wealth Partners Inc. now owns 12,355 shares of the biopharmaceutical company’s stock valued at $749,000 after acquiring an additional 259 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Bristol Myers Squibb by 6.6% during the first quarter. Parallel Advisors LLC now owns 30,078 shares of the biopharmaceutical company’s stock valued at $1,824,000 after acquiring an additional 1,868 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Bristol Myers Squibb by 12.9% during the first quarter. NewEdge Advisors LLC now owns 226,056 shares of the biopharmaceutical company’s stock worth $13,710,000 after acquiring an additional 25,771 shares during the last quarter. Finally, First Nebraska Trust Co acquired a new position in shares of Bristol Myers Squibb in the first quarter worth about $662,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.